AGH) Hematology and Medical Oncology

Topics

• Lymphoma Diagnosis and Treatment 38
• Multiple Myeloma Research and Treatments 30
• Head and Neck Cancer Studies 28
• Cancer Immunotherapy and Biomarkers 26
• Acute Myeloid Leukemia Research 25
• Hematopoietic Stem Cell Transplantation 21
• CAR-T cell therapy research 20
• Lung Cancer Treatments and Mutations 17
• Pancreatic and Hepatic Oncology Research 14
• Chronic Lymphocytic Leukemia Research 13
• Bladder and Urothelial Cancer Treatments 12
• Neuroendocrine Tumor Research Advances 12

Most cited

1. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

   The New England journal of medicine · 2022 · 656 citations · Cyrus Khan

2. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.

   Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021 · 457 citations · Gene Finley

3. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

   Lancet (London, England) · 2024 · 148 citations · Haifaa Abdulhaq

4. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.

   Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022 · 276 citations · Gene Finley

5. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).

   Blood · 2024 · 139 citations · Sara Beygi

6. NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 56 citations · Amulya Yellala

7. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.

   JAMA oncology · 2023 · 166 citations · Gene Finley

8. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.

   The Lancet. Haematology · 2024 · 85 citations · Salman Fazal